OpenAI launches AI model GPT-Rosalind for life sciences research

By Juby Babu

April 16 - OpenAI on Thursday introduced an artificial intelligence model touting increased biology knowledge and ‌scientific research capabilities, as the startup deepens its push ‌into the life sciences field.

The GPT-Rosalind, named after 20th-century British scientist Rosalind Franklin, is ​designed to support research across biochemistry, drug discovery and translational medicine.

Demand for AI-powered tools to accelerate drug discovery and research has risen across pharmaceutical companies, academic institutions and biotech firms.

"By supporting evidence ‌synthesis, hypothesis generation, experimental ⁠planning, and other multi-step research tasks, this model is designed to help researchers accelerate the early ⁠stages of discovery," OpenAI said in a blog.

Researchers using the model will be able to query databases, read the latest scientific ​papers, use ​other scientific tools and suggest ​new experiments, OpenAI said in ‌a press briefing. The model was built on top of OpenAI's newest internal models.

GPT-Rosalind is available as a research preview in ChatGPT, Codex, and the API for qualified customers through OpenAI's trusted access deployment structure. The company is also launching a ‌free Life Sciences research plugin for ​Codex, connecting scientists to over 50 ​scientific tools and data ​sources.

The company said it is working with customers ‌like Amgen, Moderna, Thermo Fisher Scientific ​and others to ​apply GPT-Rosalind across workflows.

OpenAI, creator of popular chatbot ChatGPT, on Tuesday unveiled GPT-5.4-Cyber, a variant of its latest flagship ​model fine-tuned specifically ‌for defensive cybersecurity work, following rival Anthropic's announcement of ​frontier AI model Mythos.

(Reporting by Juby Babu in Mexico ​City; Editing by Sahal Muhammed)